2022–2024 (latest 3 aligned FYs; v3 window cap 5): revenue $3M to $2.3M, decreasing; diluted EPS -0.67 to -0.31, increasing.
22
Median gross margin 29.4% over 3y, variable.
—
Not enough years of ROIC data to score returns on capital.
55
Net cash position — no leverage risk.
24
Owner earnings changed trend unclear over up to the ten most recent annual observations.
The returnsOnCapital component abstained: Not enough years of ROIC data to score returns on capital. The other four 20% weights were renormalized over the scored 80%.
Price vs. value if growth stopped today
A cautious baseline, not a price target: what the shares may support if normalized owner earnings simply hold steady.
Above value if growth stopped todayBelow value if growth stopped today
No price data
Not reported
Unavailable — insufficient owner-earnings data
Unavailable — insufficient growth-model data
Unavailable — no recent price
No price data
This zero-growth estimate assumes trailing owner earnings persist — unreliable for declining businesses. Flag status unavailable — four adjacent recent FY revenue observations are required.
Among the current top-score group, the median current price is 239% above the zero-growth estimate across 48 of the current top 50 companies by Moat Score with both values.
Missing a usable price or zero-growth estimate: ANF, BKNG.
Model details under moat-index@3.0.0: zero-growth multiple 11.1×, capped-growth comparison at no more than 18×; 9% discount rate; high-end growth 0% (capped at 4%) using min(5y revenue CAGR, 5y diluted-EPS CAGR), clamped to 0%–4%; maintenance capex uses min(capex, D&A); abstain when D&A is unavailable. This is a disclosed model range, not intrinsic value as fact.
4 years of fundamentals
The business, in plain English
Renalytix plc booked $2.3M of revenue in FY2024 in the Healthcare sector and kept 6.8% of it as gross profit — a thin-margin business by that measure. After every other cost, −1461.6% of each revenue dollar reached the bottom line.
RNLXY's latest filed year, FY2024, doesn't disclose total debt in a form the methodology can use, so current leverage is treated as unmeasured — never assumed to be zero.
This breakdown is generated from the filed numbers and sub-scores above — no outside narrative, no estimates. Where a filing doesn’t disclose an input, the sentence that would need it is omitted instead of guessed.
FY2021–FY2024 · 4 fiscal years, normalized from RNLXY’s SEC filings
Sales, as filed$2.3M FY2024Revenue kept after cost of goods6.8% FY2024Standard ROIC or separately labeled Operating ROIC
Not disclosed in RNLXY’s filings for these years — we don’t estimate it.
Cash an owner could take out−$33.5M FY2024
Gaps in a line mean that item isn’t in RNLXY’s filings for that year. The series is never interpolated or estimated. The Table view lists every filed value, including operating and net margins, total debt, and share count.
Flagship explainer
How Renalytix plc makes its money
Start with a dollar of revenue and follow what the filing says remains.
Honest partial: the filing did not provide a normalized tag for Research and development, Selling, general and administrative; those components are omitted, not plugged.
· event Jun 30, 2024 · retrieved Jul 26, 2026 · annual-row source set
Curated 19-manager tier
Who reported holding Renalytix plc
Delayed public 13F reports for 2026-Q2—not live positions, trades, or recommendations.
0 holding0 exited0 not holding0/19 resolved19 unavailable
Named manager positions and quarter-over-quarter changes
Manager
Reported position
Quarter-over-quarter
Filing accession
Abrams Capital
Unavailable
Comparison unavailable
Filing unavailable
Akre Capital
Unavailable
Comparison unavailable
Filing unavailable
Baupost Group
Unavailable
Comparison unavailable
Filing unavailable
Berkshire Hathaway
Unavailable
Comparison unavailable
Filing unavailable
Brave Warrior Advisors
Unavailable
Comparison unavailable
Filing unavailable
Dodge & Cox
Unavailable
Comparison unavailable
Filing unavailable
First Eagle
Unavailable
Comparison unavailable
Filing unavailable
Fundsmith
Unavailable
Comparison unavailable
Filing unavailable
Gardner Russo & Quinn
Unavailable
Comparison unavailable
Filing unavailable
Gates Foundation Trust
Unavailable
Comparison unavailable
Filing unavailable
Mairs & Power
Unavailable
Comparison unavailable
Filing unavailable
Markel / Markel-Gayner
Unavailable
Comparison unavailable
Filing unavailable
Oakmark / Harris Associates
Unavailable
Comparison unavailable
Filing unavailable
Pershing Square
Unavailable
Comparison unavailable
Filing unavailable
Polen Capital
Unavailable
Comparison unavailable
Filing unavailable
Sequoia / Ruane Cunniff
Unavailable
Comparison unavailable
Filing unavailable
Southeastern Asset Management
Unavailable
Comparison unavailable
Filing unavailable
Tweedy, Browne
Unavailable
Comparison unavailable
Filing unavailable
Yacktman Asset Management
Unavailable
Comparison unavailable
Filing unavailable
Position size uses shares and filed value from each manager’s 13F. Portfolio weight uses the eligible long-share filing denominator. Changes compare only with the immediately preceding calendar quarter.
The complete Form 4 source snapshot retrieved on Aug 17, 2026 contains no transaction rows.
Verified empty: the retrieved source snapshot contains no transaction event.
Source snapshot retrieved 2026-08-17T07:00:03.596Z · SEC Form 4
Moat Score history
15 logged readings since Jul 17, 2026 · append-only, never rewritten
Moat Score over timeLast scored reading of each day, on the 0–100 scale32.9 / 100
Breaks in the line mark methodology or normalizer upgrades — readings across versions aren’t compared, so a level shift there isn’t a change in the business.
Tier changesSame-methodology and same-normalizer crossings of the Wide / Narrow / Shallow bars
Scores are logged append-only and never overwritten — this record cannot be reconstructed retroactively, which is exactly why it’s worth keeping.
Insider activity
Form 4 reports mix P/S market or private transactions with compensation-plan mechanics. Activity casually described as “insider selling” can include compensation mechanics; awards, tax withholding, and option exercises are shown by their exact filed class here, never collapsed into “Bought” or “Sold.”
These are disclosed filing facts and arithmetic aggregates, not a signal or verdict.
This machine-readable surface covers SEC ownership filings from 2003; it does not represent earlier paper-era records.
No reported Form 4 transactions were found in the complete checked issuer window for RNLXY, –. The totals and cluster result below are arithmetic over that certified window.
$0
P purchases minus S sales only, Aug 17, 2025–Aug 17, 2026.
0 P / 0 S
Only P and S are included; awards, gifts, exercises, withholding, and other mechanics are excluded.
No
Requires at least 3 distinct insiders with P purchases.
Transaction-code histogram
Supporting event counts for the same certified window, Aug 17, 2025–Aug 17, 2026.
P
0
S
0
A
0
F
0
M
0
G
0
C
0
J
0
W
0
Retrieved .
Track record
How Renalytix plc’s moat rated in each of the years we can reconstruct from its filings — scored only on what was knowable at the time — and what its price and returns did afterward. The score never saw a price; the two are joined only in hindsight, for education, not as a signal.
Point-in-time scores 2020–2025, one methodology version · reconstructed from filings on file each Dec 31 — never with hindsight
Point-in-time Moat Score (dot colored by tier)Indexed price (total-return (dividends reinvested))Rated Wide-moat that year
How to read this: each dot is what the engine would have scored RNLXY on that December 31; the line below is its total-return price path (dividends reinvested) in the years since.
Two tracks, one timeline: the score has its own 0–100 scale (top), the price its own 100-based scale (bottom) — never a shared axis. The indexed price path isn't available for this company yet; gaps in the score line are years with no reconstructed rating (see the table for why). The Table view carries every value.
What followed, in the years it rated Wide
In the reconstructed history shown, RNLXY did not rate Wide-moat in any year, so there is no wide-moat track record to report. That absence is itself the honest answer — we don’t manufacture a comparison where the rating never earned one.
Healthcare context
#497 of 710 scored Healthcare companies, ranked by Moat Score.
Based on its FY2024 SEC filings, the Moat Index scores Renalytix plc (RNLXY) 32.9 out of 100 — below the Shallow-moat bar, so no moat. The five questions behind that score begin at 20% each; if exactly one genuinely lacks data, the other four weights are renormalized and disclosed. revenue and EPS trend 30, pricing power 22, returns on capital not measurable from the filings, balance-sheet safety 55, capital allocation 24.
How has RNLXY's Moat Score changed over time?
The record logs 15 readings since Jul 17, 2026; the latest reads 32.9 out of 100 (no moat). No tier changes on record yet. (Methodology or normalizer upgrades on Jul 20, 2026, Jul 23, 2026, Jul 26, 2026 re-based the score; readings across versions aren't compared.) The history is append-only — readings are only ever added, never rewritten.
Scored from primary SEC filings via the public methodology. Educational only — not a recommendation to buy or sell RNLXY. See the disclaimer.